Key result
Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
Why the study?
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
Does edoxaban prevent stroke or systemic embolism in patients with atrial fibrillation compared to warfarin?
Once-daily edoxaban is noninferior to warfarin for stroke prevention in atrial fibrillation and reduces the risk of bleeding and cardiovascular death.
Answers are grounded in this paper and cite their sources.
Edoxaban offers a safer alternative to warfarin for atrial fibrillation; confirms and extends randomized evidence for direct oral anticoagulants.
Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes. (Funded by Daiichi Sankyo Pharma Development; ENGAGE AF-TIMI 48 ClinicalTrials.gov number, NCT00781391.).
No takes yet. Share an insight, caveat, or question.
Giugliano et al. (2013) studied this question. Edoxaban was noninferior to warfarin in preventing stroke or systemic embolism, with significantly lower rates of bleeding and cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: